Magenta Therapeutics, Inc. (MGTA): Price and Financial Metrics
Magenta Therapeutics, Inc. (MGTA)
Today's Latest Price: $9.19 USD
Updated May 28 6:55pm
Add MGTA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
MGTA Stock Price Chart More Charts
MGTA Price/Volume Stats
| Current price | $9.19 | 52-week high | $16.87 |
| Prev. close | $9.42 | 52-week low | $5.76 |
| Day low | $9.09 | Volume | 156,100 |
| Day high | $9.87 | Avg. volume | 154,584 |
| 50-day MA | $8.15 | Dividend yield | N/A |
| 200-day MA | $10.87 | Market Cap | 362.86M |
Magenta Therapeutics, Inc. (MGTA) Company Bio
Magenta Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Loading social stream, please wait...